Evaluation of benazepril in cats with heart disease in a prospective, randomized, blinded, placebo‐controlled clinical trial

Evaluation of benazepril in cats with heart disease in a prospective, randomized, blinded, placebo‐controlled clinical trial

Abstract Background Heart disease is an important cause of morbidity and mortality in cats, but there is limited evidence of the benefit of any medication. Hypothesis The angiotensin‐converting enzyme inhibitor benazepril would delay the time to treatment failure in cats with heart disease of variou...

Full description

Bibliographic Details
Main Authors: Jonathan N. King, Mike Martin, Valérie Chetboul, Luca Ferasin, Anne T. French, Günther Strehlau, Wolfgang Seewald, Sarah G. W. Smith, Simon T. Swift, Susan L. Roberts, Andrea M. Harvey, Christopher J. L. Little, Sarah M. A. Caney, Kerry E. Simpson, Andrew H. Sparkes, Eleanor J. Mardell, Eric Bomassi, Claude Muller, John P. Sauvage, Armelle Diquélou, Matthias A. Schneider, Laurence J. Brown, David D. Clarke, Jean‐Francois Rousselot
Format: Article
Language:English
Published: Wiley 2019-11-01
Series:Journal of Veterinary Internal Medicine
Subjects:
ACE inhibitor
survival
treatment failure
Online Access:https://doi.org/10.1111/jvim.15572

Internet

https://doi.org/10.1111/jvim.15572

Similar Items